JP7747273B2 - ＳＡＲＳ－ＣｏＶ－２由来のアミノ酸配列およびその利用 - Google Patents

ＳＡＲＳ－ＣｏＶ－２由来のアミノ酸配列およびその利用

Info

Publication number
JP7747273B2
JP7747273B2 JP2022539616A JP2022539616A JP7747273B2 JP 7747273 B2 JP7747273 B2 JP 7747273B2 JP 2022539616 A JP2022539616 A JP 2022539616A JP 2022539616 A JP2022539616 A JP 2022539616A JP 7747273 B2 JP7747273 B2 JP 7747273B2
Authority
JP
Japan
Prior art keywords
amino acid
synthetic peptide
seq
acid sequence
serum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022539616A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022025264A1 (https=
Inventor
徹彦 吉田
菜穂子 ベイリー小林
善紀 吉田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toagosei Co Ltd
Kyoto University NUC
Original Assignee
Toagosei Co Ltd
Kyoto University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toagosei Co Ltd, Kyoto University NUC filed Critical Toagosei Co Ltd
Publication of JPWO2022025264A1 publication Critical patent/JPWO2022025264A1/ja
Application granted granted Critical
Publication of JP7747273B2 publication Critical patent/JP7747273B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
JP2022539616A 2020-07-31 2021-07-30 ＳＡＲＳ－ＣｏＶ－２由来のアミノ酸配列およびその利用 Active JP7747273B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020131022 2020-07-31
JP2020131022 2020-07-31
PCT/JP2021/028366 WO2022025264A1 (ja) 2020-07-31 2021-07-30 ＳＡＲＳ－ＣｏＶ－２由来のアミノ酸配列およびその利用

Publications (2)

Publication Number Publication Date
JPWO2022025264A1 JPWO2022025264A1 (https=) 2022-02-03
JP7747273B2 true JP7747273B2 (ja) 2025-10-01

Family

ID=80035853

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022539616A Active JP7747273B2 (ja) 2020-07-31 2021-07-30 ＳＡＲＳ－ＣｏＶ－２由来のアミノ酸配列およびその利用

Country Status (5)

Country Link
US (1) US20230272005A1 (https=)
EP (1) EP4190799A4 (https=)
JP (1) JP7747273B2 (https=)
CN (1) CN116157411A (https=)
WO (1) WO2022025264A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022308712A1 (en) * 2021-07-09 2023-12-21 Atossa Therapeutics, Inc. Compositions and methods to increase coronavirus immune response

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020028219A (ja) 2016-11-11 2020-02-27 大日本住友製薬株式会社 マラリアワクチン

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1609119A (zh) * 2003-10-23 2005-04-27 中国医学科学院药物研究所 一种肽文库、其合成方法及从该文库中筛选的活性片段
JP7297697B2 (ja) 2019-02-19 2023-06-26 キヤノンメディカルシステムズ株式会社 神経活動の領域を推定する推定方法、推定装置及び磁気共鳴イメージング装置
BR102019017792A2 (pt) * 2019-08-27 2021-11-16 Fundação Oswaldo Cruz Receptáculo proteico, método para produção do receptáculo, método de identificação de patógenos ou de diagnóstico de doenças, e, uso do receptáculo
JP2023512519A (ja) * 2020-01-31 2023-03-27 ベス イスラエル ディーコネス メディカル センター インコーポレイテッド コロナウイルス感染症を予防および処置するための組成物および方法－ｓａｒｓ－ｃｏｖ－２ワクチン
WO2021181390A1 (en) * 2020-03-09 2021-09-16 Vaxil Biotherapeutics Ltd. Antigen specific epitope–based anti-infective vaccines
TW202200199A (zh) * 2020-03-20 2022-01-01 美商百歐恩泰美國公司 冠狀病毒疫苗及使用方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020028219A (ja) 2016-11-11 2020-02-27 大日本住友製薬株式会社 マラリアワクチン

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
KHAN, M. Imran et al.，Reports of Coding-Complete Genome Sequences of Five 2019 Novel Coronavirus (SARS-CoV-2) Strains Isolated in Bangladesh，Microbiology Resource Announcements，2020年07月30日，Vol.9, Issue 31，Article number e00692-20, pp.1-2
MISHRA, Seema，T cell epitope-based vaccine design for pandemic novel coronavirus 2019-nCoV across structural and non-structural proteins，ChemRxiv, Biological and Medicinal Chemistry [online]，2020年04月03日，[retrieved on 2021.09.16], Retrieved from the Internet: <https://chemrxiv.org/engage/chemrxiv/article-details/60c749b4469df4724cf43c17>，<DOI:10.26434/chemrxiv.12029523.v2>
SINGH, Abhishek et al.，Designing a multi-epitope peptide-based vaccine against SARS-CoV-2，bioRxiv [online]，2020年04月16日，[retrieved on 2021.09.16], Retrieved from the Internet: <https://www.biorxiv.org/content/10.1101/2020.04.15.040618v1>，<DOI:https://doi.org/10.1101/2020.04.15.040618>
UL QAMAR, Muhammad Tahir et al.，Designing of a next generation multiepitope based vaccine (MEV) against SARS-COV-2: Immunoinformatics and in silico approaches，bioRxiv [online]，2020年03月22日，[retrieved on 2021.09.16], Retrieved from the Internet: <https://www.biorxiv.org/content/10.1101/2020.02.28.970343v2>，<DOI:https://doi.org/10.1101/2020.02.28.970343>
YOSHIDA, Shota et al.，SARS-CoV-2-induced humoral immunity through B cell epitope analysis and neutralizing activity in COVID-19 infected individuals in Japan，bioRxiv [online]，2020年07月23日，[retrieved on 2021.09.16], Retrieved from the Internet: <https://www.biorxiv.org/content/10.1101/2020.07.22.212761v1>，<DOI:https://doi.org/10.1101/2020.07.22.212761>

Also Published As

Publication number Publication date
WO2022025264A1 (ja) 2022-02-03
EP4190799A1 (en) 2023-06-07
US20230272005A1 (en) 2023-08-31
CN116157411A (zh) 2023-05-23
EP4190799A4 (en) 2024-08-21
JPWO2022025264A1 (https=) 2022-02-03

Similar Documents

Publication Publication Date Title
Lairmore et al. Human T-lymphotropic virus type 1 peptides in chimeric and multivalent constructs with promiscuous T-cell epitopes enhance immunogenicity and overcome genetic restriction
JP5731109B2 (ja) 疎水性ペプチドに対する抗体の製造方法
JP2003529319A (ja) ＨＩＶ−１ｇｐ４１を標的化する広範に中和する抗体を誘発する方法
JP5187883B2 (ja) 抗原ペプチドおよびその利用
Tian et al. Structure− affinity relationships in the gp41 ELDKWA epitope for the HIV‐1 neutralizing monoclonal antibody 2F5: effects of side‐chain and backbone modifications and conformational constraints
JPH04500221A (ja) インフルエンザウイルス感染症の診断および予防用合成ペプチド、およびその使用
JPH06501260A (ja) ヒト免疫不全ウィルスに対する中和抗体の誘発とワクチン接種に用いられるペプチド
CA1327096C (en) Peptides corresponding to antigenic and immunogenic determinants of major neutralizing proteins of rotaviruses
Zhao et al. Synthesis and immunological evaluation of synthetic peptide based anti-SARS-CoV-2 vaccine candidates
JPH07502484A (ja) 哺乳動物免疫不全ウイルスの検出
JPH05505188A (ja) 合成ポリペプチド
JPH02503916A (ja) Ｈｉｖエンベロープ蛋白質に関連する合成ペプチド
JP7747273B2 (ja) ＳＡＲＳ－ＣｏＶ－２由来のアミノ酸配列およびその利用
AU2001269616B2 (en) Transport peptides derived from Erns protein, cytotoxic RNase of ribosome-inactivating protein or a RSV G-protein and analogues thereof
CA1271717A (en) Polypeptides useful in vaccination against enteroviruses
EP0450715B1 (en) Immunogenic compounds, the process for their synthesis and their use in the preparation of antimalaria vaccines
EP1704167B1 (en) A method to make a peptide-carrier conjugate with a high immunogenicity
JP7598538B2 (ja) ＳＡＲＳ－ＣｏＶ－２由来のアミノ酸配列およびその利用
Du et al. Structural and immunological characterisation of heteroclitic peptide analogues corresponding to the 600–612 region of the HIV envelope gp41 glycoprotein
US5350575A (en) IBDV VP2 epitope recognized by virus neutralizing and protective monoclonal antibodies
AU2002231510B2 (en) Immunogenic formulations of variable peptidic epitopes and process for preparation thereof
Sundaram et al. Structural and immunogenicity analysis of chimeric B‐cell epitope constructs derived from the gp46 and gp21 subunits of the envelope glycoproteins of HTLV‐1
JPS63264600A (ja) ウシ白血病ウイルスに対する感染防御抗体を誘導するペプチド分画と、この分画を得る方法と、この分画の遺伝暗号配列と、この分画から製造されるワクチン
US20240182577A1 (en) Anti-pd-1 signal peptide antibody and use thereof
Francis Synthetic peptides

Legal Events

Date Code Title Description
AA64 Notification of invalidation of claim of internal priority (with term)

Free format text: JAPANESE INTERMEDIATE CODE: A241764

Effective date: 20230406

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230421

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240605

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250522

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250718

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250814

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250909

R150 Certificate of patent or registration of utility model

Ref document number: 7747273

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150